Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
Β 

ο»Ώ

15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

Β 

Share Option Schemes

Β 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

Β 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

Β 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

Β 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

Β 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

Β 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

Β 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

Β 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

Β 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

Β 

Β 

Β 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

Β 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

Β 

For further information please contact:

Β 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

Β 

About Imaginatik

Β 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

Β 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSLLFVTFRISLIF
Date   Source Headline
30th Dec 20193:10 pmRNSHalf-year Report
2nd Dec 20197:00 amRNSFinal Results
13th Nov 20197:00 amRNSAppointment of Joint Broker
28th Oct 20193:03 pmRNSDirector Declaration
27th Sep 201911:30 amRNSUpdate, Proposed Transaction and RPT
5th Sep 20194:18 pmRNSDirectorate Change
6th Aug 20197:31 amRNSRe Suspension and Update
6th Aug 20197:30 amRNSSuspension - Abal Group Plc
2nd Aug 20199:49 amRNSUpdate on suspension date
24th Jun 20199:11 amRNSUpdate on Board Changes
3rd May 20192:01 pmRNSHolding(s) in Company
3rd May 20199:00 amRNSPrice Monitoring Extension
2nd May 201911:55 amRNSHolding(s) in Company
1st May 201911:01 amRNSHolding(s) in Company
1st May 201910:58 amRNSHolding(s) in Company
29th Apr 201910:28 amRNSHolding(s) in Company
26th Apr 201911:52 amRNSHolding(s) in Company
5th Apr 20192:22 pmRNSHolding(s) in Company
1st Apr 20198:10 amRNSUpdate on Board changes
1st Mar 20197:00 amRNSUpdate and Directorate Change
5th Feb 201911:48 amRNSHolding(s) in Company
5th Feb 201910:08 amRNSCompletion of disposal
5th Feb 20198:23 amRNSHolding(s) in Company
31st Jan 20195:30 pmRNSImaginatik
31st Jan 201910:09 amRNSHolding(s) in Company
30th Jan 20199:38 amRNSHolding(s) in Company
28th Jan 201910:27 amRNSResult of GM
14th Jan 20197:00 amRNSIssue of Equity
10th Jan 20197:00 amRNSProposed sale of business and assets
13th Dec 20183:42 pmRNSHolding(s) in Company
12th Dec 201812:37 pmRNSResult of AGM
10th Dec 20183:47 pmRNSHolding(s) in Company
4th Dec 20182:10 pmRNSHolding(s) in Company
4th Dec 20189:23 amRNSHolding(s) in Company
3rd Dec 20183:01 pmRNSIssue of Equity
3rd Dec 20187:00 amRNSContract Award
28th Nov 20183:33 pmRNSHolding(s) in Company
28th Nov 20187:00 amRNSHolding(s) in Company
27th Nov 20187:00 amRNSResult of Open Offer
19th Nov 20187:00 amRNSHalf-year Report
16th Nov 20187:00 amRNSNotice of AGM
8th Nov 201812:52 pmRNSDirectorate Change
2nd Nov 20185:29 pmRNSHolding(s) in Company
2nd Nov 20187:00 amRNSOpen Offer
31st Oct 201812:37 pmRNSAdmission of new shares
26th Oct 20187:30 amRNSRestoration - Imaginatik plc
26th Oct 20187:00 amRNSAppointment of NOMAD and Completion of Placing
18th Oct 20187:00 amRNSCompany Update
1st Oct 20187:00 amRNSCompany Update
28th Sep 201811:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.